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We evaluated whether MYC, TP53, and chromosome 17 copy-number alterations occur in ACP02, ACP03, and AGP01 gastric
cancer cell lines and in their tumor counterpart. Fluorescence in situ hybridization for MYC and TP53 genes and for chromosome
17 was applied in the 6th, 12th, 60th, and 85th passages of the cell lines and in their parental primary tumors. We observed that
three and four MYC signals were the most common alterations in gastric cell lines and tumors. ACP02 presented cells with two
copies of chr17 and loss of one copy of TP53 more frequently than ACP03 and AGP01. Only ACP03 and AGP01 presented clonal
chr17 trisomy with three or two TP53 copies. The frequency of MYC gain, TP53 loss, and chromosome 17 trisomy seems to
increase in gastric cell lines compared to their parental tumors. Our findings reveal that these cell lines retain, in vitro, the genetic
alterations presented in their parental primary tumors.
1. Introduction
Chromosomal instability is characterized by changes in chro-
mosome copy number (aneuploidy) and alterations in chro-
mosomal regions, which may induce oncogene activation,
tumor suppressor gene inactivation, or both. Chromosomal
instability is one of the two major genomic instability path-
ways observed in gastric cancer (GC) [1], the fourth most
frequent type of cancer and second most frequent cause of
cancer mortality worldwide [2]. However, due to the diﬃ-
culty in obtaining high-quality chromosome preparations in
these neoplasias, the evaluation of chromosomal alterations
is complicated [3–7].
Cell lines derived from human cancers are useful in
order to understand the chromosomal alterations and other
molecular alterations in the carcinogenesis process. Cell lines
are also a useful tool for the study of anticancer treatments in
vitro and in animal xenograft models. However, the process
of cell line immortalization has been implicated as a source
of cytogenetic changes, and growth passages have been asso-
ciated with random genomic instability [8–11]. Given their
importance as models, it is important to understand in which
way and to what degree cell lines grown under artificial con-
ditions reflect their parental in vivo genetic architecture [8].
Our research group previously established three GC cell
lines from tumor samples of individuals from Northern
Brazil. ACP02 cell line was established from a diﬀuse-type
GC, and ACP03 and AGP01 were from an intestinal-type
GC. These cell lines exhibited a composite karyotype with
several clonal chromosomal alterations. All these cell lines
presented chromosome 8 trisomy—where MYC oncogene
is located—and deletion of chromosome arm 17p, which
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includes the TP53 tumor suppressor locus. Moreover,
chromosome 17 (chr17) trisomy in ACP03 and AGP01 cell
lines was detected [12].
Here, we analyzed the number of MYC, TP53, and chr17
copies in 6th (short-duration culture), 12th (long-duration
culture), 60th and 85th passages of ACP02, ACP03 and
AGP01 cell lines, and in their parental primary tumors. We
aim to evaluate whether these gene/chromosomal alterations
occur in cell lines and in their tumor counterpart, as well as
whether multiple passage growth leads to a diﬀerence in the
frequency of these alterations.
2. Materials andMethods
FISH was performed on recently made slides from methanol/
acetic acid fixed cells of four passages (6th, 12th, 60th, and
85th) of ACP02, ACP03, and AGP01 cell lines, as previously
described [13]. FISH was also applied on nuclei isolated
from parental primary tumors as previously reported [14].
Tumor samples were obtained from Joa˜o de Barros Barreto
University Hospital (HUJBB) in Para´ State, Brazil.
To determine MYC gene copy number, cells were hybrid-
ized with a rhodamine-labeled probe (Chromotrax, USA) for
MYC gene region (8q24.1-q24.2). To determine the chro-
mosome 17 and TP53 copy numbers, cells were hybridized
using a dual-color direct labeled probe (Qbiogene, USA)
specific for chr17 α-satellite and for TP53 gene region, and
labeled with fluorescein and rhodamine, respectively. Nuclei
were counterstained with DAPI/antifade (Chemicon, USA).
Fluorescence was detected using an Olympus BX41 fluores-
cence microscope with DAPI/FITC/TRICT filters (Olympus,
Japan), and signals were analyzed using FISHView of Applied
Spectral Imaging image analysis system (ASI Ldt., Israel). For
each cell line or tumor, 200 interphase nuclei were analyzed
and scored using the criteria of Hopman et al. [15]. To avoid
misinterpretation due to technical error, gastric mucosal
tissue (nonneoplastic) and normal lymphocyte nuclei were
used as control.
For statistical analysis, the MYC, TP53, or chr17 copy
numbers were compared among cell lines using Krus-
kal-Wallis nonparametric test followed by Games-Howell
posthoc test. Friedman test followed by Wilcoxon posthoc
test with Bonferroni correction were used to evaluate differ-
ences among primary tumor and their cell line passages. In
all analyses, the confidence interval was 95%, and P values
less than .05 were considered significant.
3. Results
3.1. MYC. Two signals for MYC probe were observed in
99.5% of peripheral blood lymphocytes and in 97% of nor-
mal gastric cells (Figure 1(a)). Table 1 shows the frequency
of MYC signals in cell lines and parental tumors. In primary
tumor samples, three MYC signals were the most frequent
alteration, ranging from 39%–45% of cells (Figure 1(b)). In
the 6th and 12th passages, 3 MYC signals were the most
frequent alteration (about 40%) followed by 4 signals (about
28%). In the 60th passage of cell lines, 3 and 4 MYC signals
were commonly observed. In the 85th passage, the most
frequent alteration was the presence of 4 signals for MYC
probe, ranging from 33.5%–42% of cells. Five or more MYC
copies by cells were also observed in all cell lines and parental
tumors. High amplification of MYC was detected as clonal
alteration mainly in cell lines (Figure 1(c)).
Statistical analysis revealed that the frequency of cells
with high MYC amplification was significantly diﬀerent
among ACP02, ACP03, and AGP01 cell lines (χ2 = 9.206,
df = 2, P = .01, by Kruskal-Wallis test). The Games-Howell
posthoc analyses demonstrated that the ACP02, cell line, and
parental tumor, presented a lower frequency of high MYC
amplification cells than AGP01 (P = .019) and ACP03 (P =
.014).
Concerning the MYC signal frequency during culture
process, we observed that the frequency of cells with 2 (χ2 =
10.933, df = 4, P = .027, by Friedman test), 4 (χ2 = 10.667,
df = 4, P = .031, by Friedman Test), 5 or more (χ2 = 11.467,
df = 4, P = .022, by Friedman test), and high amplification
(χ2 = 11.429, df = 4, P = .022, by Friedman test) MYC
copies were significantly diﬀerent among parental tumor and
their passages. However, the posthoc analysis by Wilcoxon
test with Bonferroni correction did not reveal any significant
diﬀerence, probably due to the gradual alterations among
passages (Figures 2(a), 2(b), 2(c), 2(d)).
3.2. Chr17/TP53. Two signals for chr17 and TP53 were
observed in about 97% of control cells (Figure 1(d)). Table 2
shows the frequency of chr17/TP53 signals in cell lines from
the 6th, 12th, 60th, and 85th passages and tumor samples.
The frequency of cells with 2 signals for chr17 and 2
signals for TP53 was significantly diﬀerent among ACP02,
ACP03, and AGP01 cell lines (χ2 = 6, df = 2, P = .05,
by Kruskal-Wallis test). The Games-Howell posthoc analyses
demonstrated that the ACP02, cell line, and parental tumor
presented a higher number of this cell type than AGP01.
ACP02 also presented a higher frequency of cells with two
copies of chr17 than AGP01 (P = .003, by Games-Howell
posthoc analysis) and ACP03 (P = .009, by Games-Howell
posthoc analysis).
The frequency of cells with 2/1 (χ2 = 10.839, df = 2,
P = .004, by Kruskal-Wallis test), 2/3 (χ2 = 11.423, df = 2,
P = .003, by Kruskal-Wallis test), and 3/3 (χ2 = 10.691, df =
2, P = .005, by Kruskal-Wallis test) copies of chr17/TP53 was
significantly diﬀerent among cell lines. The Games-Howell
posthoc analyses demonstrated that the ACP02 presented a
higher frequency of cells with 2 copies of chr17 and loss of
TP53 than AGP01 (P = .001) and ACP03 (P = .001). In
ACP02, the most common alteration observed was the loss
of one copy of TP53 (Figure 1(e)).
Only ACP03 and AGP01 presented clonal chr17 trisomy
with two or three copies of TP53. Thus, the Games-Howell
posthoc analysis among cell lines also demonstrated that
AGP01 and ACP03 presented a higher frequency of cells with
chr17 trisomy with 2 TP53 copies than ACP02 (P = .035 and
P = .15, resp.; Figure 1(f)). AGP01 also presented a higher
frequency of cells with chr17 trisomy and 3 TP53 copies than
ACP02 (P = .013).
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Figure 1: Fluorescence in situ hybridization assay. (a) Interphase nuclei presenting two MYC signals from normal gastric mucosa; (b)
interphase nuclei presenting 2–5 MYC signals from ACP02 parental primary tumor; (c) interphase nuclei presenting MYC signal number
alterations, including high amplification, from the 85th passage of AGP01 cell line; (d) interphase and metaphase cells presenting two copies
of chr17/TP53 from lymphocytes control, with the green spots representing the 17 centromere probe and the red representing the TP53
gene probe; (e) interphase nuclei presenting two signals of chr17 and two or one TP53 signal(s) from ACP02 parental primary tumor; (f)
interphase nuclei presenting three signals for chr17 and two TP53 signals from the 85th passage of ACP03 cell line.
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Table 1: FISH analysis of MYC copy number in gastric cancer cell lines, in their parental primary tumors and in control samples.
Nuclei exhibiting MYC signals, no. (%)a
1 signal 2 signals 3 signals 4 signals ≥5 signals HA
ACP02
Parental primary tumor 0 (0) 57 (28.5) 78 (39) 57 (28.5) 8 (4) 0 (0)
6th passage 1 (0.5) 40 (20) 84 (42) 62 (31) 13 (6.5) 0(0)
12th passage 0 (0) 34 (17) 88 (44) 63 (31.5) 15 (7.5) 0(0)
60th passage 0 (0) 6 (3) 83 (41.5) 79 (39.5) 24 (12.5) 7 (3.5)
85th passage 2 (1) 8 (4) 65 (32.5) 84 (42) 30 (15) 11 (5.5)
ACP03
Parental primary tumor 0 (0) 39 (19.5) 84 (42) 41 (20.5) 23 (11.5) 13 (6.5)
6th passage 0(0) 33 (16.5) 89 (44.5) 40 (20) 24 (12) 14 (7)
12th passage 1 (0.5) 19 (9.5) 85 (42.5) 51 (25.5) 29 (14.5) 15 (7.5)
60th passage 1 (0.5) 8 (4) 71 (35.5) 63 (31.5) 39 (19.5) 18 (9)
85th passage 0 (0) 6 (3) 47 (23.5) 69 (34.5) 49 (24.5) 29 (14.5)
AGP01
Parental primary tumor 0 (0) 47 (23.5) 90 (45) 37 (18.5) 17 (8.5) 9 (4.5)
6th passage 4 (2) 12 (6) 69 (34.5) 59 (29.5) 36 (18) 20 (10)
12th passage 1 (0.5) 13 (6.5) 70 (35) 56 (28) 33 (16.5) 27 (13.5)
60th passage 0 (0) 2 (1) 64 (32) 63 (31.5) 41 (20.5) 30 (15)
85th passage 1 (0.5) 1 (0.5) 45 (22.5) 67 (33.5) 49 (24.5) 37 (18.5)
Control
Normal stomach tissue 4 (2) 194 (97) 2 (1) 0 (0) 0 (0) 0 (0)
Lymphocytes 1 (0.5) 199 (99.5) 0 (0) 0 (0) 0 (0) 0 (0)
a
The FISH analysis was performed on 200 nuclei. HA: high amplification.
Table 2: FISH analysis of chr17/TP53 copy number in gastric cancer cell lines, in their parental primary tumors and in control samples.
Nuclei exhibiting chr17/TP53 signals, no. (%)a
1/0 signal 1/1 signals 2/1 signals 2/2 signals 2/3 signals 3/2 signals 3/3 signals
ACP02
Parental primary tumor 3 (1.5) 4 (2) 63 (31.5) 130 (65) 0 (0) 0 (0) 0 (0)
6th passage 2 (1) 4 (2) 62 (31) 132 (66) 0 (0) 0 (0) 0 (0)
12th passage 0 (0) 7 (3.5) 73 (36.5) 120 (60) 0 (0) 0 (0) 0 (0)
60th passage 1 (0.5) 10 (5) 84 (42) 104 (52) 1 (0.5) 0 (0) 0 (0)
85th passage 2 (1) 25 (12.5) 102 (51) 69 (34.5) 1 (0.5) 0 (0) 1 (0.5)
ACP03
Parental primary tumor 2 (1) 14 (7) 17 (8.5) 100 (50) 0 (0) 54 (27) 13 (6.5)
6th passage 3 (1.5) 15 (7.5) 14 (7) 86 (43) 3 (1.5) 47 (23.5) 32 (16)
12th passage 4 (2) 8 (4) 9 (4.5) 75 (37.5) 4 (2) 55 (27.5) 45 (22.5)
60th passage 1 (0.5) 1 (0.5) 2 (1) 21 (10.5) 2 (1) 70 (35) 103 (51.5)
85th passage 3 (1.5) 0 (0) 5 (2.5) 6 (3) 5 (2.5) 121 (60.5) 60 (30)
AGP01
Parental primary tumor 6 (3) 29 (14.5) 7 (3.5) 116 (58) 4 (2) 12 (6) 26 (13)
6th passage 5 (2.5) 12 (6) 4 (2) 36 (18) 0 (0) 31 (15.5) 112 (56)
12th passage 0 (0) 9 (4.5) 3 (1.5) 35 (17.5) 6 (3) 37 (18.5) 110 (55)
60th passage 4 (2) 4 (2) 0 (0) 30 (15) 5 (2.5) 36 (18) 121 (60.5)
85th passage 3 (1.5) 7 (3.5) 0 (0) 23 (11.5) 3 (1.5) 70 (35) 94 (47)
Control
Normal stomach tissue 0 (0) 4 (2) 1 (0.5) 193 (96.5) 0 (0) 0 (0) 2 (1)
Lymphocytes 0 (0) 3 (1.5) 1 (0.5) 195 (97.5) 1 (0.5) 0 (0) 0 (0)
a
The FISH analysis was performed on 200 nuclei.
Concerning the chr17 and TP53 alterations during cul-
ture process, we observed that the frequency of cells with two
copies of chr17/TP53 (χ2 = 11.467, df = 4, P = .022, by
Friedman test), two chr17 copies (χ2 = 10.373, df = 4, P =
.035, by Friedman test), and chr17 trisomy (χ2 = 10.4, df =
4, P = .034, by Friedman test) were significantly diﬀerent
among parental tumor and their passages. However, the
posthoc analysis by Wilcoxon test with Bonferroni correction
did not reveal any significant diﬀerence, probably due to the
gradual alterations among passages (Figures 2(e), 2(f), 2(g),
2(h)).
4. Discussion
Fluorescence in situ hybridization (FISH) assay allows rapid
detection of numerical genetic aberrations in interphase
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Figure 2: Continued.
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Figure 2: Distribution of cells according to (a) MYC signals in AGP01 parental tumor and cell line passages; (b) MYC signals in ACP02
parental tumor and cell line passages; (c) MYC signals in ACP03 parental tumor and cell line passages; (d) mean of MYC signals of AGP01,
ACP02, and ACP03 parental tumor and cell line passages; (e) TP53/chr17 signals in AGP01 parental tumor and cell line passages; (f)
TP53/chr17 signals in ACP02 parental tumor and cell line passages; (g) TP53/chr17 signals in ACP03 parental tumor and cell line passages;
(h) mean of TP53/chr17 signals of AGP01, ACP02, and ACP03 parental tumor and cell line passages.
nuclei in tumor cells. FISH assay should be used to evaluate
cell-to-cell heterogeneity in gene or loci copy number and
detect small subpopulations of genetically aberrant cells
[16]. Using FISH assay, our research group previously
reported several frequent aneusomies in GC samples and cell
lines from individuals of Northern Brazil, which suggests a
genomic instability [7, 12, 13, 17–20]. Molecular cytogenetic
studies have shown that gains at 3q, 7p, 7q, 8q, 13q, 17q,
20p, and 20q and losses at 4q, 9p, 17p, and 18q are recurrent
chromosomal alterations in GC. (For a review, see [21].)
Our research group has observed that chr8 trisomy,
where MYC is located, is present in almost all gastric tumors
and cell lines from our population by conventional and
molecular cytogenetic analyses [7, 12, 13, 17, 19, 20, 22,
23]. We have previously described that ACP02, ACP03, and
AGP01 at the 60th passage presented chr8 trisomy, as well
as tetrasomy. In these cell lines, more than 5 signals of chr8
were observed in less than 5% of cells [12]. However, MYC
copy number seems to be higher than the number of chr8
copies in our studies [19, 20, 23]. High MYC amplification
has frequently been observed in primary tumors from
our population, and we have also previously reported that
MYC can be inserted into other chromosomes. The higher
frequency of MYC high amplification in ACP03 and AGP01,
originated from intestinal-type GC, than ACP02, originated
from a diﬀuse-type GC, agrees with our previous observation
in primary GC. Our group had observed that clonal high
amplification of MYC is less frequent in diﬀuse-type than
intestinal-type primary GC [19, 20, 23].
Thus, the presence of three or more copies of MYC,
including gene high amplification, in all samples of the
present study corroborates our previous observations in
primary GC. Moreover, the frequency of MYC gain in
advanced GC observed by FISH seems to be higher in our
population than in East Asia, which ranges from 15.5%
to 48% of cases [6, 24, 25]. MYC amplification has been
suggested as the main mechanism for its deregulation in GC
(see review [26]).
Concerning TP53/chr17 copies, we observed that ACP02,
cell line, and its parental tumor, presented cells with two
copies of chr17 and loss of one copy of TP53 more frequently
than ACP03 and AGP01. This finding corroborates our
previous study using dual-color FISH for chr17/TP53 in
primary tumor samples, in which we observed that the
frequency of cells with two chr17 and one TP53 signals was
higher in the diﬀuse-type than in the intestinal-type GC
[27].
We also observed that only ACP03 and AGP01 cells and
parental tumors presented chr17 trisomy as clonal alteration,
in agreement with the karyotype of these cell lines at 60th
passage [12]. Although primary tumors of individuals from
Northern Brazil present clonal crh17 trisomy or monosomy
by FISH analysis [27], chr17 aneusomy is not the most
frequent alteration within primary tumors of our population
[7, 22, 28].
Moreover, we detected TP53 loss in all cell lines and
primary tumors. TP53 somatic alteration is described in
about 50% of human cancers, including GC [29]. Deletion of
chromosome arm 17p was also observed in ACP02, ACP03,
and AGP01 by conventional cytogenetic analysis [12]. In
our population, TP53 deletion was previously observed
in all analyzed primary tumor samples, despite Laure´n’s
histopathologic types; therefore, corroborating the present
study [27].
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Although we did not observe any significant diﬀerence
among parental tumors and their cell line passages after
posthoc analysis, we were able to observe that the number of
MYC signals is significantly higher in cell lines than primary
tumors. We also observed a reduction in the number of
nuclei with two signals for chr17/TP53 when we compared
GC cell lines with their parental tumors, which reflects an
increase of aneusomy cells.
Tumor samples are usually composed of a heterogeneous
clonal population which can include nonneoplastic cells.
The increased frequency of cells with MYC gain, TP53 loss,
and chr17 trisomy in cell lines may be due to the selection
of a subpopulation of cancer cells during the cell line
establishment. Normal cells can divide only a limited number
of times in vitro, because of replicative senescence. However,
some tumor cells can become immortal and, therefore, they
do not undergo senescence when cultured in vitro [30].
According to the Hayflick limit, the maximum number of
passages that a normal cell attains before senescence is about
50 [31]. Here, we evaluated GC cell lines in the 60th and
in 85th passages, which select cells with genomic alterations
that are essential for cell survival and proliferation in vitro.
A meta-analysis of the studies using comparative
genomic hybridization assay to evaluate chromosomal alter-
ations in cancer cell lines and primary tumors demonstrated
that, on average, the relatively large-scale copy number
genetic aberrations seen in cell lines in vitro accurately reflect
their parent histology [8]. In this meta-analysis study, it was
also reported that MYC oncogene amplification seems to be
more frequent in cell lines in several histologies, indicating
that the deregulation of this gene may be acquired as part of
cell immortalization or that their occurrence is selected when
tumors are chosen for transformation. Therefore, we suggest
that, in our GC cell lines, cells with MYC amplification are
selected during the long culture process.
5. Conclusion
Our findings reveal that ACP02, ACP03, and AGP01 cell
lines retain in vitro the genetic alterations presented in their
parental primary tumors. Thus, these findings suggest that
these cell lines are an interesting model to study GC biology
as well as to evaluate new anticancer strategies.
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